This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
8 Sep 2011

Merck Serono & F-Star Collaborate for Novel Targeted Biologics

Austria's F-Starfor announced yesterday the agreement with Merck Serono for the discovery of new antibody-derived therapeutics against inflammatory disease targets.

Merck Serono has signed a research, license and commercialisation agreement with Austria's antibody engineering company F-Star, for the discovery of new antibody-derived therapeutics against inflammatory disease targets with F-Star's Modular Antibody Technology.

 

Merck Serono will nominate up to three therapeutic targets and the parties will collaborate to jointly discover mono-specific Fc-based targeted biologics (Fcabs) and bi-specific IgG-based targeted biologics (mAb2), for which Merck KGaA will have exclusive worldwide development and commercialisation rights.

 

Vienna-based F-Star will receive an initial technology access fee and research-based funding and is eligible to receive additional licence fees, development, regulatory and commerc

Related News